The China Mail - New hope for patients with less common breast cancer

USD -
AED 3.672501
AFN 69.999752
ALL 82.403169
AMD 383.760301
ANG 1.789679
AOA 916.999889
ARS 1185.2553
AUD 1.539955
AWG 1.80125
AZN 1.675304
BAM 1.717535
BBD 2.018204
BDT 122.146455
BGN 1.71288
BHD 0.377046
BIF 2975.573129
BMD 1
BND 1.289325
BOB 6.906787
BRL 5.6339
BSD 0.999794
BTN 85.833842
BWP 13.426656
BYN 3.271174
BYR 19600
BZD 2.007842
CAD 1.367765
CDF 2864.99952
CHF 0.818219
CLF 0.024447
CLP 938.150131
CNY 7.204297
CNH 7.174565
COP 4108.67
CRC 508.371131
CUC 1
CUP 26.5
CVE 96.832408
CZK 21.73285
DJF 177.720143
DKK 6.531197
DOP 59.021375
DZD 131.622061
EGP 49.668203
ERN 15
ETB 134.150246
EUR 0.87559
FJD 2.24825
FKP 0.73964
GBP 0.737905
GEL 2.73969
GGP 0.73964
GHS 10.247336
GIP 0.73964
GMD 71.999851
GNF 8663.273954
GTQ 7.681466
GYD 209.119849
HKD 7.844215
HNL 25.999766
HRK 6.596899
HTG 130.767914
HUF 353.140042
IDR 16297.3
ILS 3.48442
IMP 0.73964
INR 85.90375
IQD 1310
IRR 42124.999987
ISK 126.62042
JEP 0.73964
JMD 159.441481
JOD 0.709036
JPY 142.717993
KES 129.504804
KGS 87.449806
KHR 4019.999874
KMF 431.000397
KPW 899.96547
KRW 1362.790079
KWD 0.30632
KYD 0.832964
KZT 510.145029
LAK 21599.999781
LBP 89600.000175
LKR 299.167929
LRD 198.649826
LSL 18.20432
LTL 2.95274
LVL 0.60489
LYD 5.453468
MAD 9.196858
MDL 17.252932
MGA 4519.999896
MKD 53.881414
MMK 2099.552513
MNT 3575.627882
MOP 8.079336
MRU 39.592874
MUR 45.802891
MVR 15.459766
MWK 1735.000381
MXN 19.201502
MYR 4.232499
MZN 64.010411
NAD 18.26157
NGN 1580.149575
NIO 36.799176
NOK 10.110761
NPR 137.335178
NZD 1.659045
OMR 0.384507
PAB 0.99953
PEN 3.656499
PGK 4.119499
PHP 55.734984
PKR 282.001098
PLN 3.747377
PYG 7987.038078
QAR 3.644443
RON 4.420902
RSD 102.617051
RUB 79.249696
RWF 1414.325923
SAR 3.750585
SBD 8.343939
SCR 14.21698
SDG 600.496907
SEK 9.583196
SGD 1.286055
SHP 0.785843
SLE 22.720069
SLL 20969.500214
SOS 571.501438
SRD 37.050119
STD 20697.981008
SVC 8.745823
SYP 13001.858184
SZL 18.200902
THB 32.598731
TJS 9.895716
TMT 3.5
TND 2.98
TOP 2.3421
TRY 39.282401
TTD 6.774184
TWD 29.957
TZS 2683.204007
UAH 41.435026
UGX 3640.00404
UYU 41.678559
UZS 12844.999831
VES 94.846525
VND 26084
VUV 120.579269
WST 2.74951
XAF 576.050197
XAG 0.028973
XAU 0.000296
XCD 2.70255
XDR 0.716787
XOF 573.999518
XPF 104.749903
YER 243.85012
ZAR 17.817801
ZMK 9001.199783
ZMW 25.813732
ZWL 321.999592
  • RBGPF

    -1.5000

    67.5

    -2.22%

  • CMSC

    0.0899

    22.2

    +0.4%

  • BCE

    0.0100

    21.96

    +0.05%

  • BCC

    -0.0050

    87.54

    -0.01%

  • CMSD

    0.0587

    22.21

    +0.26%

  • NGG

    -0.2700

    71.05

    -0.38%

  • SCS

    -0.1600

    10.37

    -1.54%

  • AZN

    1.1800

    73

    +1.62%

  • GSK

    0.3300

    40.8

    +0.81%

  • RIO

    -0.3000

    58.55

    -0.51%

  • RELX

    0.2950

    54.36

    +0.54%

  • BTI

    -0.1750

    46.17

    -0.38%

  • JRI

    -0.0400

    12.94

    -0.31%

  • RYCEF

    0.1150

    12.15

    +0.95%

  • VOD

    -0.0450

    10.26

    -0.44%

  • BP

    -0.6350

    28.92

    -2.2%

New hope for patients with less common breast cancer
New hope for patients with less common breast cancer / Photo: © AFP/File

New hope for patients with less common breast cancer

A new treatment nearly halves the risk of disease progression or death from a less common form of breast cancer that hasn't seen major drug advances in over a decade, researchers reported Monday.

Text size:

Results from the study, presented at the annual meeting of the American Society for Clinical Oncology, are expected to be submitted to regulators and could soon establish a new first-line therapy for people with HER2-positive metastatic breast cancer -- the advanced stage of a form that comprises 15–20 percent of all breast cancer cases.

HER2-positive cancers are fueled by an overactive HER2 gene, which makes too much of a protein called human epidermal growth factor receptor 2 that helps cancer cells grow and spread.

Patients with HER2-positive breast cancer that has spread to other parts of the body live around five years.

"Seeing such a striking improvement was really impressive to us -- we were taking a standard and almost doubling how long patients could have their cancer controlled for," oncologist Sara Tolaney, chief of the breast oncology division at Dana-Farber Cancer Institute, told AFP.

The current standard of care, known as THP, combines chemotherapy with two antibodies that block growth signals from the HER2 protein. The new approach uses a drug called trastuzumab deruxtecan (T-DXd), an antibody attached to a chemotherapy drug.

- 'Smart bomb' -

This "smart bomb" strategy allows the drug to target cancer cells directly. "You can bind to the cancer cell and dump all that chemo right into the cancer cells," explained Tolaney.

"Some people call them smart bombs because they're delivering chemo in a targeted fashion -- which is how I think we're able to really increase efficacy so much."

Common side effects included nausea, diarrhea and a low white blood cell count, with a less common effect involving lung scarring.

T-DXd is already approved as a "second-line" option -- used when first-line treatments stop working. But in the new trial, it was given earlier, paired with another antibody, pertuzumab.

In a global trial led by Tolaney, just under 400 patients were randomly assigned to receive T-DXd in combination with pertuzumab, thought to enhance its effects.

A similar number received the standard THP regimen. A third group, who received T-DXd without pertuzumab, was also enrolled -- but those results haven't yet been reported.

- 44 percent risk reduction -

At a follow-up of 2.5 years, the T-DXd and pertuzumab combination reduced the risk of disease progression or death by 44 percent compared to standard care.

Fifteen percent of patients in the T-DXd group saw their cancer disappear entirely, compared to 8.5 percent in the THP group.

Because this was an interim analysis, the median progression-free survival -- meaning the point at which half the patients had seen their cancer return or worsen -- was 40.7 months with the new treatment, compared to 26.9 months with the standard, and could rise further as more data come in.

Tolaney said the results would be submitted to regulators around the world, including the US Food and Drug Administration, and that future work would focus on optimizing how long patients remain on the treatment, particularly those showing complete remission.

"This represents a new first-line standard treatment option for HER2-positive metastatic breast cancer," said Dr. Rebecca Dent, a breast cancer specialist at the National Cancer Center Singapore who was not involved in the study

Q.Moore--ThChM